RxDoctor Payments Data

John Mehl, MD

Interventional Cardiology · Fort Smith, ARNPI 1255359931

Payments from drug & device makers

$1,137in general payments, 2019–2025

Across 59 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$330
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$196
  • Edwards Lifesciences$158
  • Medtronic$101
  • Abbott$96
  • Johnson & Johnson$65
  • plus $191 from 7 others

What the payments were for

  • Food & beverage$1,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,137 in reported general payments places this provider in the 5th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$127,830
Medicare patients
596
Services billed
1,578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$162,398
EntrestoSacubitril/Valsartan167$125,188
XareltoRivaroxaban88$89,225
Repatha SureclickEvolocumab27$23,622
BrilintaTicagrelor47$22,356
FarxigaDapagliflozin Propanediol28$21,209
JardianceEmpagliflozin18$10,667
Metoprolol Succinate412$5,378
Ranolazine ErRanolazine64$4,094
ClopidogrelClopidogrel Bisulfate289$2,598
BystolicNebivolol Hcl12$1,940
Digoxin124$1,816
Nebivolol Hcl31$1,517
Atorvastatin Calcium182$1,446
Bisoprolol Fumarate68$1,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$330$125,188167 claims
Johnson & JohnsonXarelto$65$89,22588 claims
Boehringer IngelheimJardiance$16$10,66718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →